Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07520344

Wearable Photoplethysmography for Non-invasive Hydration Assessment

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
PepsiCo Global R&D · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Hydration status during exercise is often determined by measuring body mass change, fluid intake and urine output. However, obtaining these measurements can be an invasive, time-consuming process. Hydration status may be detectable by analyzing blood flow patterns of the superficial (just under the skin) blood vessels. Wearable devices are now abundant among the general population, and despite attempts from several groups, a hydration status metric based on noninvasive wearable device metrics has not been developed. With wearables, a light source connected to an optical sensor transmits and reflects light through the body. The light sensor detects absorption of the light based on wavelength measurements of the detected light. Absorption of specific wavelengths of light energy is dependent upon the amount of oxygenated blood in the vessels. When the vessels expand and relax, the amount of blood volume in the observed tissue increases and decreases potentially causing a shift in the photoplethysmography (PPG) wave detected by the wearable. The shift in the shape of the PPG wave may be detected in a way that indicates the relative change in tissue hydration levels. However, to our knowledge, no wrist worn device that utilizes PPG has been successfully able to predict hydration status. Therefore, this study aims to utilize photoplethysmography (PPG) technology in a wearable device to accomplish this approach to hydration monitoring.

Conditions

Interventions

TypeNameDescription
OTHERExercisePerform stationary cycling exercise in the laboratory for 2 30- minute bouts at a standardized exercise intensity (wattage) that elicits 50-80% heart rate max determined by equation (208-(70% of age))

Timeline

Start date
2026-04-01
Primary completion
2026-09-01
Completion
2026-10-01
First posted
2026-04-09
Last updated
2026-04-09

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT07520344. Inclusion in this directory is not an endorsement.